Navigation Links
Merck Serono Named as a Top Employer by Science Magazine
Date:10/9/2008

tions as employers.

About Merck Serono

Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux(R)), multiple sclerosis (Rebif(R)), infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)).

With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 31,946 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.net or http://www.merck.de


'/>"/>
SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance
4. New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
5. Merck & Co., Inc. Named Keynote Sponsor For Diversity Alliance For Sciences Inaugural Conference
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
9. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
10. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
11. EMD Serono Named as a Top Employer by Science Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology ... offer to purchase all of the outstanding shares of Avigen, ... share, announced today that it has extended the expiration date ... time, on Friday, April 3, 2009. The tender offer was ...
... March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... focused on endocrine therapy and oncology, will announce its ... before market open on Wednesday, March 11, 2009. The ... discuss these results later that same day at 10:00 ...
... Award to Middletown High School SophomoreBRISTOL, R.I., March 6 ... of encouraging young women to pursue careers in science ... a full-scholarship award for one participant during the 2009 ... Simanski, sophomore at Middletown High School, was presented today ...
Cached Biology Technology:BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009 3GRRL Tech Participant Offered Full Tuition Four-Year Scholarship to Roger Williams University 2GRRL Tech Participant Offered Full Tuition Four-Year Scholarship to Roger Williams University 3
(Date:10/15/2014)... to bacterial pneumonia in female mice to an enzyme ... are naturally more resistant to respiratory infections than males. ... increased resistance to bacterial pneumonia in female mice is ... They also show that this enzyme is ultimately activated ... , The team, lead by Professor Lester Kobzik at ...
(Date:10/15/2014)... , Oct. 15, 2014   Neurotechnology ... today announced the availability of the VeriLook ... Surveillance 3.0 provides real-time biometric face identification using ... digital surveillance cameras. The new version not only ... differentiates people from objects while they are moving ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... in collaboration with European research institutes ICFO (Barcelona) ... light behaves in complex photonic materials inspired by ... the limit of light resolution at the nanoscale ... and matter interact, which could lead to the ...
... that we understand the brain, the more complex it ... and neurobiology of psychiatric disorders. For "Mendelian" disorders, like ... a single clinical disorder, following relatively simple genetic principals. ... extremely challenging. Its biology is not well understood and ...
... VILNIUS, Lithuania, Aug. 20, 2012   Neurotechnology , a ... vision technologies, today announced the availability of NPointer, a ... simple hand gestures instead of a mouse or touch ... free download, requires no special hardware, just a standard ...
Cached Biology News:Scientists shed light on glowing materials 2Scientists shed light on glowing materials 3Making sense out of the biological matrix of bipolar disorder 2NPointer from Neurotechnology Uses Hand Gestures to Control and Navigate Computer Programs Without a Mouse or Touchpad 2